NICE rethinks gudiance on Sanofi-Aventis's Multaq
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has reconsidered its preliminary negative recommendations on Sanofi-Aventis's Multaq (dronedarone) for patients with atrial fibrillation (AF). Concerns from patients and clinicians seem to have swayed the institute.